Hank McKinnell
Hank McKinnell
Henry A. McKinnell, Jr.is the former chief executive officer and former chairman of the board of directors of Pfizer Inc. He is also a director of ExxonMobil and Moody's...
coming difficult easy estimate fourth fully last quarter second share soon sure understand year
What analysts are coming to understand is that comparisons to last year are particularly difficult in the second quarter, ... And what I am sure they will soon understand is that comparisons are particularly easy in the fourth quarter and that makes our estimate of $1.56 to $1.60 (per share for 2002) fully achievable.
companies pipeline quite together
Quite frankly, with the two companies together we can get more out of the pipeline than we could separately.
looks quit rate
Our drug looks like it can take the quit rate up to 50 percent,
actions build driving key medicines newly pipeline series specific supporting taking
We are supporting our key in-line and newly launched medicines, driving important new medicines through the pipeline and taking a series of specific actions to build Pfizer's value.
consistent court decision encourage exist laws lower medical millions patent patients principle support undermine
Lipitor is one of the most important medical breakthroughs of our era, and millions of patients have used it to lower their cholesterol. This court decision is consistent with the fundamental principle that patent laws exist to support and encourage medical innovators, not undermine them.
company expenses lots places sales trim turn
Frankly, there are lots of other places in the company to trim expenses before you would turn to the sales force.
based business continued growth job winning
Based on today's survey, we see job growth and continued investment, a winning combination at this part of the business cycle.
compared competition declined growth half increased key lower markets quarter rate reflected third versus
Revenues in the third quarter of 2005 reflected lower prescription growth and increased competition in key therapeutic markets in the U.S., such as the lipid-lowering market, where the rate of growth in the third quarter declined significantly versus the first half of the year; and the erectile dysfunction market, which has been in decline compared to 2004.
estimate given million nearly people treated
On any given day, we estimate that nearly 40 million people around the world are treated with a Pfizer medicine,
access allow balanced foreign investors reasonable satisfies security sure time united
There has to be a balanced approach, which first satisfies our need for security and at the same time makes sure we allow reasonable access to foreign investors to the United States.
add additional business confidence fill increasing jobs opposed payroll people permanent point seeing trying willing
You are seeing business confidence increasing to the point where people are willing to add permanent jobs to the payroll as opposed to trying to fill that need through additional overtime.
business conditions current financial light prior prospects
We are evaluating our financial prospects in light of current and anticipated business conditions and are withdrawing our prior guidance.
business conditions current financial guidance light prior prospects
We are evaluating our financial prospects for 2006 and 2007 in light of current and anticipated business conditions and are withdrawing our prior guidance for those years,
dramatic looks lowering maybe raising risk
It looks like a combination of raising HDL and lowering LDL cholesterol could have dramatic impact, maybe eliminating cardiovascular risk,